Gainers

• Lakewood-Amedex (NASDAQ:LABT) stock rose 20.4% to $0.34 during Wednesday's after-market session.
• Glaukos (NYSE:GKOS) stock rose 16.85% to $212.01. The company's market cap stands at $10.6 billion. As per the press release, Q3 earnings came out today.
• Bausch Health Companies (NYSE:BHC) stock increased by 11.05% to $7.68. The market value of their outstanding shares is at $2.3 billion. As per the press release, Q3 earnings came out today.
• Teladoc Health (NYSE:TDOC) shares moved upwards by 9.01% to $7.5. The market value of their outstanding shares is at $1.1 billion. As per the news, the Q3 earnings report came out today.
• Pomdoctor (NASDAQ:POM) shares rose 7.77% to $1.94. The company's market cap stands at $3.8 million.
• Accuray (NASDAQ:ARAY) stock moved upwards by 6.87% to $0.14. The market value of their outstanding shares is at $15.8 million.

Losers

• CDT Equity (NASDAQ:CDT) shares decreased by 13.2% to $0.07 during Wednesday's after-market session.
• LENZ Therapeutics (NASDAQ:LENZ) stock decreased by 12.91% to $2.8. The company's market cap stands at $98.9 million. As per the press release, Q3 earnings came out today.
• Community Health System (NYSE:CYH) shares declined by 11.28% to $2.36. The market value of their outstanding shares is at $400.4 million. As per the news, the Q3 earnings report came out today.
• MiMedx Group (NASDAQ:MDXG) stock decreased by 9.37% to $3.58. The market value of their outstanding shares is at $569.1 million. As per the press release, Q3 earnings came out today.
• cbdMD (AMEX:YCBD) stock decreased by 6.61% to $0.35. The market value of their outstanding shares is at $4.1 million.
• Streamex (NASDAQ:STEX) stock decreased by 6.42% to $0.39. The company's market cap stands at $47.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.